This policy excerpt provides coverage and prior-authorization requirements for a broad set of pharmacy and specialty drugs on the Blue Cross Blue Shield – South Carolina formulary (Formulary ID: 25385, effective 12/01/2025). It defines product-specific coverage conditions (diagnosis confirmation, biomarker or genetic testing when required, age/weight limits), step-therapy expectations (trial and failure, contraindication, or intolerance — “TF/C/I” — to specified conventional therapies), and documentation needed to support approvals (e.g., recent lab values, imaging, pathology, or specialist consultation).
Most products are available only when the clinical prerequisites listed in each entry are met; common elements across entries include: requirement for a documented diagnosis and indication-specific objective data, prescriber specialty recommendations for select agents, and authorization durations typically of 6 months initial for some biologic/acute starts and 12 months for maintenance or reauthorization. Continuation of previously authorized therapy is explicitly approvable when the patient demonstrates a positive clinical response. The document also notes exclusions and not-medically-necessary uses (for example, restrictions on combining certain classes such as injectable CGRP inhibitors for migraine prevention and exclusion of pyrimethamine for malaria prophylaxis).
Providers requesting prior authorization should supply the diagnosis and the specific supporting clinical information required for the drug and indication (for example, genetic or biomarker test results performed by an FDA-cleared or CLIA-certified laboratory, recent lab thresholds, documentation of TF/C/I to listed comparators, and specialist consultation where indicated). Absent the required documentation or failure to meet the indication-specific criteria may result in denial.